

## Chlamydia, Chlamydothila, CPN

**CPNhelp.org (2005):** Emerging information about Chlamydia pneumoniae in disease & its treatment. Neueste Informationen zu Chlamydia pneumoniae als Krankheitserreger und dessen Behandlung. <http://cpnhelp.org/>

**“What diseases has it been implicated in? Welche Krankheiten sind vorwiegend involviert?** [Multiple sclerosis](#), Chronic fatigue, [Asthma](#), Arthritis, Fibromyalgia, Chronic refractory sinusitis, [Cardiac disease](#), [Interstitial cystitis](#), Prostatitis, Crohn's disease, Inflammatory bowel disease<sup>i</sup>, [Alzheimer's disease](#)

**Additionally: Zusätzlich:** chronic obstructive pulmonary disease, uveitis, optic neuritis, radiculitis, nerve deafness, transverse myelitis, sarcoid, myocarditis, pericarditis, culture-negative endocarditis, atheromatous arterial disease, aneurysm, giant-cell (temporal) arteritis, polyarteritis nodosa, Wegener's granuloma, primary sclerosing cholangitis, reactive arthritis, Reiter's syndrome, Behcet's disease, cutaneous vasculitides including pyoderma gangrenosa. Wheldon adds: "Conditions which may suggest the possibility of flare-ups of chronic Chlamydia pneumoniae infection deserving serological investigation include the following — a multiplicity being more strongly suggestive: recurrent sinusitis, recurrent chest infections<sup>i</sup>, chronic fatigue (especially if following a respiratory infection), focal neurological deficits, myalgia, muscle fasciculation's, recurrent episodes of bronchospasm, unexplained pleuritic pain, angina, recurrent arthralgia, unexplained recurrent abdominal pain, unexplained menorrhagia, recurrent fistula-in-ano, recurrent cutaneous vasculitides, achalasia, intestinal dysmotility.

**Treatment** can take months to years to completely eradicate Cpn from the body.

**Die Behandlung** kann Monate bis Jahre dauern bis zu einer vollständigen Heilung".

Stratton C. Chlamydothila pneumonia. Respiratory tract syndrome.

<http://www.cpnhelp.org/twar/twar-syndrome.htm>

Zeidler H, et al. (2014) **New insights into Chlamydia and arthritis. Promise of a cure?** Ann Rheum Dis 73, 637–644. doi:10.1136/annrheumdis-2013-204110

<http://ard.bmj.com/content/early/2013/12/02/annrheumdis-2013-204110.abstract>

**Supplements** to Protect Cells and Foster Regeneration Specific to Cpn Infection (2005)

**Ergänzende Medikamente** um Zellen zu schützen und um regenerative Vorgänge zu fördern, speziell bei der aktiven Infektion mit Cpn (2005)

<http://www.cpnhelp.org/publicimages/allsupplementschart.html>

N-acetyl-Cysteine, Acetyl L-Carnitin, Selenium, Ubichinone (coenzyme Q), Alpha-lipoic acid, [Magnesium](#), Omega 3 fish oil, Vitamin B12 i.v, i.m., Vitamins B, folic acid, L-Tryptophan, SAME, Probiotics, [Quercetin](#); cabbages, Garlic etc.

Wheldon D. (2003 / 2013) Empirical antibacterial treatment of infection with Chlamydothila pneumoniae in Multiple Sclerosis <http://www.davidwheldon.co.uk/ms-treatment.html>

Berghoff W. (2011) Pathophysiologische Hypothese Chlamydothila pneumoniae / Multiple Sklerose (sogenanntes Wheldon-Protokoll) [http://www.praxis-berghoff.de/dokumente/pathophysiologische\\_hypothese\\_chlamydothila\\_pneumoniae\\_ms.pdf](http://www.praxis-berghoff.de/dokumente/pathophysiologische_hypothese_chlamydothila_pneumoniae_ms.pdf)

**MS Cure?** <http://www.abc.net.au/catalyst/stories/3572695.htm>

Rifampin (2012) <http://www.kabilahsystems.de/rifampicin.pdf>

Virchow R (1863, 1971) Cellular pathology as based upon physiological and pathological histology, 2nd Ed. J. B. Lippincott, Philadelphia, Pa. **[the difference between Ateromatosis and Arteriosclerosis]** <https://archive.org/details/cellularpatholog00virchow>

Osler W (1908). **Diseases of the arteries**, p.426–447. In W. Osler and T. MacCrae (ed.), Modern medicine: its theory and practice in original contributions by American and foreign authors. Lea & Febiger, Philadelphia, Pa.

Tunstall LH (1963) Microbiological studies on pleural fluids of coronary thrombosis patients. Ph.D Dissertation, Wayne State University, Detroit.

Altmeier WA (1972) **L-Form of bacteria may cause thrombi**. Infect Dis 2,1

Barbour AG, Amano K-I, Hackstadt T et al. (1982) Chlamydia trachomatis has penicillin-binding proteins but not detectable muramic acid. J. Bacteriol. 151, 420-428.

Jones R B, Ridgway G L, Boulding S, Hunley K L. (1983) **In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis**. Rev Infect Dis. 5 (Suppl. 3), S556–S561. [PubMed](#)

Kurtzke JF, Hyllested K. (1986) **Multiple sclerosis in the Faroe Islands II**. Clinical update, transmission, and the nature of MS. Neu-rology 36, 307-38.

Leinonen M, Linnanmäki MK, Nimitinen MS et al. (1990) **Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction**. Microb. Pathogen. 9, 67-73

Ridgway G L, Mumtaz G, Fenelon L. (1991) The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR) J Antimicrob Chemother. 27(Suppl. A), 43–45. [PubMed](#)

Agacfidan A, Moncada J, Schachter J. (1993) In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother. 37, 1746–1748. [PMC free article](#) [PubMed](#)

Hammerschlag M R. (1994) Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother. 38, 1873–1878. [PMC free article](#) [PubMed](#)

Niki Y, Kimura M, Miyashita N, Soejima R. (1994) In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia. Antimicrob Agents Chemother. 38, 2296–2299. [PMC free article](#) [PubMed](#)

Kuo C-C, Jackson L A, Campbell L A, Grayston J T. (1995) Chlamydia pneumoniae (TWAR) Clin Microbiol Rev. 8, 451–461. [PMC free article](#) [PubMed](#)

Grayston JT, Kuo CC, Coulson AS, Camp-bell LA, et al. (1995) Chlamydia pneumonia (TWAR) in atherosclerosis of the carotid artery. Circulation 92, 3397-400

Malinverni R, Kuo C C, Campbell L A, Lee A, Grayston J T. (1995) Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis. Antimicrob Agents Chemother. 39, 45–49. [PMC free article](#) [PubMed](#)

Saikka P. (1995) Chronic Chlamydia pneumonia infections. In: Allegra L, Blasi F, editors. Chlamydia pneumoniae infection. Mai-land: Springer, 51-64

Eliopoulos G M, Moellering R C., Jr . Antimicrobial combinations. (1996) In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, Md: Williams & Wilkins 330–393.

Gnarpe J, Eriksson K, Gnarpe H. (1996) In vitro activities of azithromycin and doxycycline against 15 isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother. 40, 1843–1845 [PMC free article](#) [PubMed](#)

Gump D W. (1996) Antimicrobial susceptibility testing for some atypical microorganisms: chlamydiae, mycoplasmas, Rickettsia, and spirochetes. In: Lorian V, editor. Antibiotics in laboratory medicine. Baltimore, Md: Williams & Wilkins 212–229

Kuo C-C, Jackson L A, Lee A, Grayston J T. (1996) In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother. 40, 2669–2670. [PMC free article](#) [PubMed](#)

Welsh L, Gaydos C, Quinn T. (1996) In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae. Antimicrob Agents Chemother. 40, 212–214. [PMC free article](#) [PubMed](#)

Ramirez J. A. (1996) Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann. Intern. Med. 125:979–982. [Medline](#)

Saikku, Pekka. (1996) Chlamydia pneumonia and cardiovascular diseases. Clin Micro-biol Infect 1(Suppl 1), 19-22.

Ånestad G, Scheel O, Hungnes O. (1997) Chronic infections and coronary heart disease. Lancet 350. 1028

Gupta S, Leatham E W, Carrington D, Mendall M A, Kaski J C, Camm A J. (1997) Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 96, 404–407. [PubMed](#)

Nystromrosander C, Hulten K, Gustavson I, Cars O, Engstrand L, Hjelm E. (1997) Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline—methodological aspects of the determination of minimal inhibitory and minimal bactericidal concentrations. Scand J Infect Dis. 29, 513–516. [PubMed](#)

Stratton CW, Mitchell WM (1997) The pathogenesis of Systemic Chlamydial Infections: Theoretical Considerations of Host Cell Energy Depletion and Its metabolic Consequences. Antimicrobics and Infectious Disease:15es Newsletter 16(5)

Stille W, Dittmann R, Just-Nuebling G. (1997) Atherosclerosis due to chronic arteritis caused by Chlamydia pneumoniae: a tentative hypothesis. Infection 25. Mün-chen: MMV Medizin Verlag GmbH,

Lüderitz, B (1997) Ist die Koronarsklerose eine Infektionskrankheit? Deutsches Ärzteblatt 18, 950-951

Marre, R. Essig, A (1997) Chlamydia pneumoniae und Arteriosklerose. Deutsche Medizinische Wochenschrift 122 (38), 1092-1095

Marre, R. Essig, A (1997) Diagnostik und Therapie von Chlamydieninfektionen. Deutsche Medizinische Wochenschrift 122 (31/32), 971-975

Schattenfroh, S (1997) Die These ist alt, der Erreger ist neu: Arteriosklerose eine Infektionskrankheit? Deutsche Medizinische Wochenschrift 122 (16), 7-8

Schattenfroh, S (1997) Arteriosklerose-Erregern auf der Spur. Deutsche Medizinische Wochenschrift 122 (41), A9-A10

Stille, W (1997) Arteriosklerose - eine Infektion durch Chlamydia pneumoniae. Deutsche Medizinische Wochenschrift 122 (36), 1086-1091

Gabler-Sandberger, E (1998) Chlamydien im Atheromen: Vorsicht bei Interpretation. Deutsche Medizinische Wochenschrift 123 (6), A12

Pai J, Knoop F C, Hunter W J III. (1998) Chlamydia pneumoniae and occlusive vascular disease: identification and characterization. J. Pharmacol. Toxicol. Methods 39, 51–61. [CrossRefMedline](#)

Yamashita K, Ouchi K, Shirai M et al. (1998) Distribution of Chlamydia pneumoniae infection in the atherosclerotic carotid artery. Stroke 29, 773-778. [PubMed](#)

Hahn D L, Werner N L. (1998) Age-dependent associations of acute vascular events with prior antibiotic prescriptions: implications for treatment trials of Chlamydia-associated atherosclerosis. In: Stephens R S, Byrne G I, Christiansen G, et al. Chlamydial infections. San Francisco, Calif: International Chlamydia Symposium 183–186

Roblin P M, Hammerschlag M R. (1998) Microbiologic efficacy of azithromycin and susceptibilities of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother. 42, 194–196. [PMC free article PubMed](#)

Sinisalo J, Mattila K, Nieminen M S, Valtonen V, Syrjälä M, Sundberg S, Saikku P. (1998) The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother. 41, 85–92. [PubMed](#)

Stille W, Stephan Chr (1998) Argumente für eine Antibiotika-Therapie der multiplen Sklerose. Könnten Chlamydien eine Ursache sein? Chemotherapie Journal 7. Jahrgg, Heft 4, 143-146 [http://www.p-e-g.org/publikationen/ctj/143\\_146.pdf](http://www.p-e-g.org/publikationen/ctj/143_146.pdf)

Meniconi A, Noll G, Lüscher TF. (1998) Ist die Arteriosklerose eine Infektionskrankheit? Schweiz Rundsch Med Prax 87, 64-74.

Balin BJ, Gérard HC, Arking EJ et al. (1998) **Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain.** Med Mikrobiol Immunol 187, 23-42 <http://www.ncbi.nlm.nih.gov/pubmed/9749980>

WEISS H-E, WEISS H, NOLTE O, SONNTAG H-G (1999) Internationale Patentanmeldung Nr. WO0038712: **Method for producing autogenous vaccines for treating chlamydial infections in mammals and humans.**

Freidank HM, Losch P, Vögele H et al. (1999) **In Vitro** Susceptibilities of Chlamydia pneumoniae Isolates from German Patients and Synergistic Activity of Antibiotic Combinations. Antimicrobial Agents and Chemotherapy, 43(7) 1808-1810, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC89372/>  
**[Synergistische Effekte von Azithromycin + Rifampicin + Doxycyclin]**

Ewald PW (2000) Plague Time. How Stealth Infections cause Cancers, Heart Disease, and other deadly Ailments. The Free Press. ISBN 0-684-86900-4

Rödel J, Woytas M, Groh A, Schmidt KH, Hartmann M, Lehmann M, Straube E (2000) - Production of basic fibroblast growth factor and interleukin 6 by human smooth muscle cells following infection with Chlamydia pneumoniae. Infect Immun 68, 3635-3641.

Libby P (2000) Changing concepts of atherogenesis. J. Intern. Med. 247,349-358. [[PubMed](#)]

Dreses-Werringloer U, Padubrin I, Zeidler H, Kohler L (2001) **Effects of azithromycin and rifampin** on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother 45, 3001–8. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC90774/>  
„**Additionally, the combination of rifampin and azithromycin proved to be more efficient than azithromycin alone, in that elimination of typical and aberrant inclusions and suppression of rRNA synthesis occurred earlier. ... Finally, we can assume that such a combination may possibly represent a new treatment strategy.** »

Mahony J B, Coombes BK. (2001) Chlamydia pneumoniae and atherosclerosis: does the evidence support a causal or contributory role? FEMS Microbiol. Lett. 197, 1-9. [[PubMed](#)]

Derfuss T, Hohlfeld R, Meinel E (2001) Multiple sclerosis. Chlamydia hypothesis in debate. Nervenarzt 72(10), 820-3. [Abstract](#)

Derfuss T, Gürkov R, Then Bergh F, et al. (2001) Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response. Brain 124(Pt 7), 1325-35. [Abstract](#)

**Mattman L** (2001) Cell Wall Deficient Forms. Stealth Pathogens. 3<sup>rd</sup> Edition. CRC Press. P. 129-132 **L-Forms in Thrombi.**

Boman J, Hammerschlag MR (2002) Chlamydia pneumoniae and Atherosclerosis: Critical Assessment of Diagnostic Methods and Relevance to Treatment Studies. Clin Microbiol Rev. 15(1), 1–20. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC118057/>

[Villareal C](#), [Whittum-Hudson JA](#), [Hudson AP](#) (2002) Persistent Chlamydiae and chronic arthritis. PMCID: PMC130142 Arthritis Res. 4(1) 5–9. Published online. doi: [10.1186/ar382](https://doi.org/10.1186/ar382)

Marek S, Mahony J, Petrich A et al. (2002) Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infectious Diseases 2, 21 doi:10.1186/1471-2334-2-21 <http://www.biomedcentral.com/1471-2334/2/21>  
“**C. pneumoniae DNA detection was associated with CV disease in unadjusted case-control studies. However, adjustment for potentially confounding measures such as smoking or season, and standardization of laboratory methods, are needed to confirm this association.**”

Selzman C H, Netea MG, Zimmermann MA et al. (2003) Atherogenic effects of Chlamydia pneumoniae: refuting the innocent bystander hypothesis. J. Thorac. Cardiovasc. Surg. 126, 688-693. [[PubMed](#)]

Yoneda H, Miura K, Matsushima H et al. (2003) **Aspirin** inhibits Chlamydia pneumoniae-induced NFκB activation, cyclo-oxygenase-2 expression and prostaglandin E<sub>2</sub> synthesis and **attenuates** chlamydial growth. J. Med. Microbiol. 52:409-415. [[PubMed](#)]

Carter JD, Valeriano J, Vasey FB (2004) **Doxycycline versus doxycycline and rifampin** in undifferentiated spondyloarthritis, with special reference to chlamydia-induced arthritis: a prospective, random-ized 9-month comparison. J Rheumatol 31, 1973–80.

<http://www.ncbi.nlm.nih.gov/pubmed/15468362> [[Abstract/FREE Full text](#)]  
„**CONCLUSION: The combination of doxycycline and rifampin for 9 months seemed to be effective in treatment of chronic uSpA. This is the first study to demonstrate therapeutic benefit with antimicrobials to a chronic inflammatory arthritis possibly secondary to persistent Chlamydia.**“

Siewert K, Rupp J, Matthias Klinger M et al. (2005) Growth Cycle-Dependent Pharmacodynamics of Antichlamydial Drugs. 0066-4804/05/\$08.00!0  
doi:10.1128/AAC.49.5.1852–1856.2005 American Society for Microbiology.

Stratton CW, Wheldon DB (2006) Multiple sclerosis: an infectious syndrome involving Chlamydia pneumoniae. TRENDS in Microbiology Vol.14 No.11

Stratton CW, Wheldon DB (2007) Antimicrobial Treatment of Multiple Sclerosis. Infection URBAN & VOGEL

Rupp J, Werner Solbach W, Gieffers J (2007) Prevalence, genetic conservation and transmissibility of the Chlamydia pneumoniae bacteriophage (Cpn1). FEMS Microbiol Lett 273, 45–49 <http://onlinelibrary.wiley.com/doi/10.1111/j.1574-6968.2007.00785.x/pdf>

Carter et al. (2009) Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis & Rheumatism, 60 (5), 1311 DOI: [10.1002/art.24431](https://doi.org/10.1002/art.24431)

Carter JD, Espinoza LR, Inman RD et al. (2010) **Combination Antibiotics as a Treatment for Chronic Chlamydia-Induced Reactive Arthritis. A Double-Blind, Placebo-Controlled, Prospective Trial.** *Arthritis Rheum.* 62(5), 1298–1307. doi: [10.1002/art.27394](https://doi.org/10.1002/art.27394) PMID: PMC2907099 NIHMSID: NIHMS190581 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907099/>  
« These data suggest that a 6-month course of combination antibiotics [Acithromycin and rifampicin] is an effective therapy for chronic Chlamydia-induced ReA. »

Shima K, Kuhlenbäumer G, Rupp J (2010) [Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember?](https://doi.org/10.1007/s00430-010-0162-1) Med Microbiol Immunol. 199(4), 283-9. doi: 10.1007/s00430-010-0162-1. Epub 2010 May 6. Review. PMID: 20445987

Contini C, Seraceni S, Cultrera R et al. (2010) Chlamydia pneumoniae Infection and Its Role in Neurological Disorders. Interdisciplinary Perspectives on Infectious Diseases Volume 2010, Article ID 273573, 18 pages doi:10.1155/2010/273573

Shima K, Szaszák M, Solbach W, Gieffers J, Rupp J (2011) **Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.** Antimicrob Agents Chemother. 55(5), 2319-24. PubMed [PMID: 21321137.](https://pubmed.ncbi.nlm.nih.gov/21321137/)

Haider M, Rizvi M, Malik A, et al. (2011) Acute and chronic Chlamydia pneumoniae infection and inflammatory markers in coronary artery disease patients. J Infect Dev Ctries 5(8), 580-6. [Abstract](#)

Kēniņa V, Auce P, Millers A (2011) The relationship between seropositivity against Chlamydia pneumoniae and stroke and its subtypes in a Latvian population. Medicina (Kaunas) 47(12), 657-60. [Abstract](#)

Hrubá D, Kodat V, Krásný J, et al. (2011) Serological findings of Chlamydial pneumoniae in the Czech Republic--control group of patients examined in the study: Chlamydia pneumoniae in the aetiology of keratoconjunctivitis sicca. Cas Lek Cesk 150(12), 656-9. [Abstract](#)

Kumar S, Saigal SR, Sethi GR (2011) Detection of IgM and IgG antibodies to Chlamydia pneumoniae in pediatric community-acquired lower respiratory tract infections. Indian J Pathol Microbiol 54(4), 782-5. [Abstract](#)

Rai NK, Choudhary R, Bhatia R, Singh MB, Tripathi M, Prasad K, Padma MV. (2011) Chlamydia pneumoniae seropositivity in adults with acute ischemic stroke: A case-control study. Ann Indian Acad Neurol [serial online] 14:93-7. <http://www.annalsofian.org/text.asp?2011/14/2/93/82792>

[www.chlamydiae.com](http://www.chlamydiae.com) professional. (2011) <http://www.chlamydiae.com/restricted/default.asp>

Rosenfeld ME, Campbell LA (2011) Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. *Thromb Haemost* 106(5), 858-67. [Abstract](#)

Baud D, Greub G (2011) Intracellular bacteria and adverse pregnancy outcomes. *Clin Microbiol Infect* 17(9), 1312-22. [Abstract](#)

Davutoğlu V, Ercan S, Oylumlu M (2011) Microorganisms and valve tissue/ demonstration of *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, Cytomegalovirus, and Epstein-Barr virus in atherosclerotic coronary arteries, nonrheumatic calcific aortic and rheumatic stenotic mitral valves by polymerase chain reaction. *Anadolu Kardiyol Derg* 11(6), 564; author reply 564-5. [Full Citation](#) | [Publisher Full Text](#) | [Find Related Articles](#)

Berghoff W. (2011) **Pathophysiologische Hypothese *Chlamydia pneumoniae* / Multiple Sklerose** (sogenanntes Wheldon-Protokoll)  
[http://www.praxis-berghoff.de/dokumente/pathophysiologische\\_hypothese\\_chlamydia\\_pneumoniae\\_ms.pdf](http://www.praxis-berghoff.de/dokumente/pathophysiologische_hypothese_chlamydia_pneumoniae_ms.pdf)

Deniset JF, Hedley TE, Dibrov E, et al. (2012) *Chlamydia pneumoniae* infection induces alterations in vascular contractile responses. *Am J Pathol* 180(3), 1264-72. [Abstract](#)

Luque A, Turu MM, Rovira N, et al. (2012) Early atherosclerotic plaques show evidence of infection by *Chlamydia pneum.* *Front Biosci (Elite Ed)*. 4, 2423-32. [Abstract](#)

Padmavati S, Gupta U, Agarwal HK (2012) Chronic infections & coronary artery disease with special reference to *Chlamydia pneumoniae*. *Indian J Med Res* 228-32. [Abstract](#)

Khandhadia S, Foster S, Cree A, et al. (2012) *Chlamydia* infection status, genotype, and age-related macular degeneration. *Mol Vis* 29-37. [Abstract](#)

Benagiano M, Munari F, Ciervo A, et al. (2012) *Chlamydia pneumoniae* phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. *Proc Natl Acad Sci U S A* 109(4), 1222-7. [Abstract](#)

Sagynbaeva VE, Lazebnik LB, Kniazev OV, et al. (2012) Isolation of antibodies to *Chlamydia* and *Mycoplasma pneumoniae* during the immunosuppressive therapy of patients with inflammatory bowel disease. *Eksp Klin Gastroenterol* (3), 40-6. [Abstract](#)

[Romano JD](#), [de Beaumont C](#), [Carrasco JA](#) et al. (2012) Fierce competition between *Toxoplasma* and *Chlamydia* for host cell structures in dually infected cells. *Eukaryot Cell*.  
<http://www.ncbi.nlm.nih.gov/pubmed/23243063>

Szaszák M, Shima K, Käding N, Hannus M, Solbach W, Rupp J (2013) **Host metabolism promotes growth of *Chlamydia pneumoniae* in a low oxygen environment.** *Int J Med Microbiol*. 303(5), 239-46. PubMed [PMID: 23665044](#).

[Śliwa-Dominiak J](#), [Suszyńska E](#), [Pawlikowska M](#), [Deptuła W](#). (2013) ***Chlamydia* bacteriophages.** *Arch Microbiol*. 195(10-11) 765-71. doi: 10.1007/s00203-013-0912-8. Epub 2013 Aug 1. <https://www.ncbi.nlm.nih.gov/pubmed/23903989>

Chumduri C, Gurumurthy RK, Zadora PK et al. (2013) ***Chlamydia* infection promotes host DNA damage and proliferation but impairs the DNA damage response.** *Cell Host & Microbe* <http://www.cell.com/cell-host-microbe/abstract/S1931-3128%2813%2900193-5>

[Pitt RA](#), [Alexander S](#), [Horner PJ](#) et al. (2013) **Presentation of clinically suspected persistent chlamydial infection: a case series.** Int J STD AIDS. 24(6), 469-75. doi: 10.1177/0956462412472815. <http://www.ncbi.nlm.nih.gov/pubmed/23970750>

**Zeidler H, et al. (2014) New insights into Chlamydia and arthritis. Promise of a cure?** Ann Rheum Dis 73, 637–644. doi:10.1136/annrheumdis-2013-204110

“**Identification of Chlamydia and/or other bacteria in joints initiated several studies to test various antibiotics for their elimination of pathogens from that site; all trials using antibiotic monotherapy were unsuccessful. However, a recent trial demonstrated positive results using an antibiotic combination in chronic SpA, with a special focus on Chlamydia. This was followed by a study in patients with demonstrated CRa which showed that a 6-month course of combination therapy with rifampicin (300 mg/day) plus doxycycline (200 mg/day), or plus azithromycin (500 mg/day followed by 5 days of 2–500 mg once/week) is effective in eliminating pathogens, giving improvement of arthritis; patients in this study were shown to be PCR-positive either in blood or joint fluid for C trachomatis or C pneumoniae. A response was observed in 63% versus 22%, and complete remission was observed in 20% versus 0% under active treatment compared with placebo, respectively.** The combination of azithromycin and rifampin was most effective, although the study was not powered to determine which combination of antibiotics is superior. These results open for the first time the prospect for curative treatment. However, the effectiveness of this approach must be confirmed in additional studies, especially in patients diagnosed only by serology and clinical manifestations for chlamydial infection.”  
<http://ard.bmj.com/content/early/2013/12/02/annrheumdis-2013-204110.abstract>

**Croxatto A, Rieille N, Kernif T et al. (2014) Presence of Chlamydiales DNA in ticks and fleas suggests that ticks are carriers of Chlamydiae.** Ticks and Tick-borne Diseases.

<http://www.ncbi.nlm.nih.gov/pubmed/24698831>

[http://www.labor-spiez.ch/de/the/bs/pdf/Croxatto\\_et\\_al\\_2014\\_Presence\\_of\\_Chlamydiales\\_DNA\\_in\\_ticks\\_and\\_fleas.pdf](http://www.labor-spiez.ch/de/the/bs/pdf/Croxatto_et_al_2014_Presence_of_Chlamydiales_DNA_in_ticks_and_fleas.pdf)

„**Thus, ticks may carry Chlamydiales and should thus be considered as possible vectors for Chlamydiales propagation to both humans and animals.**“

**Borel N, Pospischil A, Hudson AP et al (2014) The role of viable but non-infectious developmental forms in chlamydial biology.** Front. Cell. Infect. Microbiol., | doi:

10.3389/fcimb.2014.00097 <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109588/>

<http://journal.frontiersin.org/Journal/10.3389/fcimb.2014.00097/full>

**Käding N, Szaszák M, Rupp J (2014) Imaging of Chlamydia and host cell metabolism.** Future Microbiol. 9(4), 509-21. doi: 10.2217/fmb.14.13. Review. PMID: 24810350

**Lim C, Hammond CJ, Hingley ST et al. (2014) Chlamydia pneumoniae infection of monocytes in vitro stimulates innate and adaptive immune responses relevant to those in Alzheimer’s disease.** J Neuroinflammation. 11(1), 5.

<http://www.ncbi.nlm.nih.gov/pubmed/?term=25540075>

„**Conclusions Utilizing RT-PCR and ELISA techniques, our data demonstrate that Cpn infection of THP1 human monocytes promotes an innate immune response and suggests a potential role in the initiation of inflammation in sporadic/late-onset Alzheimer’s disease.**“

**Shima K, Klinger M, Schütze S, Kaufhold I, Solbach W, Reiling N, Rupp J (2015) The role of ER-related BiP/GRP78 in IFN-γ induced persistent Chlamydia pneumoniae infection.** Cell Microbiol. doi: 10.1111/cmi.12416. <http://www.ncbi.nlm.nih.gov/pubmed/25588955>

« **Direct interaction of Chlamydiae with the endoplasmic reticulum (ER) is essential in intracellular productive infection.** »

ClinicalTrials.gov (2015) **Combination Antibiotic Treatment for Reactive Arthritis Caused by Chlamydia Bacteria** Phase 3 Trial to Assess the Efficacy of Long-Term (6 Months)

Combination Antibiotics as a Treatment for Chlamydia-Induced Reactive Arthritis.

<https://clinicaltrials.gov/ct2/show/NCT00351273>

[**Acithromycin and Rifampicin or Doxycyclin and Rifampicin or Placebo**]

**Dumke R, Schnee Chr, Pletz MW et al. Mycoplasma pneumonia and Chlamydia spp. Infection in Community-Acquired Pneumonia Germany, 2011-2012.** Emerging Infectious Diseases 21(3), 426-434 [http://wwwnc.cdc.gov/eid/article/21/3/14-0927\\_article](http://wwwnc.cdc.gov/eid/article/21/3/14-0927_article)



<http://wwwnc.cdc.gov/eid/article/21/3/pdfs/14-0927.pdf>

[Krämer S](#), [Crauwels P](#), [Bohn R](#) et al. (2015) **AP-1 transcription factor serves as a molecular switch between Chlamydia pneumoniae replication and persistence.**

Infection and Immunity. doi: 10.1128/IAI.03083-14

<http://iai.asm.org/content/early/2015/04/14/IAI.03083-14.abstract>

Sarkar A, Möller S, Bhattacharyya A et al. (2015) **Mechanisms of apoptosis inhibition in Chlamydia pneumoniae-infected neutrophils.** International Journal of Medical Microbiology xxx (2015) xxx–xxx <http://www.ncbi.nlm.nih.gov/pubmed/26005182>

[Shima K](#), [Coopmeiners J](#), [Graspeuntner S](#), [Dalhoff K](#), [Rupp J](#) (2016) **Impact of micro-environmental changes on respiratory tract infections caused by intracellular bacteria.**

[FEBS Lett](#). doi: 10.1002/1873-3468.12353. [Epub ahead of print]

<http://www.ncbi.nlm.nih.gov/pubmed/27509029>

**Recent publications using MLST in Chlamydiales research (2016)**

<http://pubmlst.org/chlamydiales/references.shtml> <http://pubmlst.org/>

Unbound MEDLINE results for: Chlamydia pneumoniae AND human [Refine this search](#)

Unbound MEDLINE results for: Chlamydia pneumoniae AND human [Refine this search](#)

- ➔ **L-Formen, Bakterien-Pleomorphie** <http://www.erlebnishaft.de/stressvar1.pdf>
- ➔ **Angiopathie, Vasculitis** <http://www.xerlebnishaft.de/angiopathie.pdf>
- ➔ **Gen – Dynamik** [http://www.xerlebnishaft.de/gen\\_dynamik.pdf](http://www.xerlebnishaft.de/gen_dynamik.pdf)
- ➔ **Multiple Sklerose – Borreliose** <http://www.erlebnishaft.de/multipleskleroseborreliose.pdf>
- ➔ **Alzheimer** <http://www.erlebnishaft.de/alzheimerspirochaetosis.pdf>

- ➔ **Chlamydia pneumoniae eine Übersicht über evtl. weitere Therapie-Angebote**  
<http://www.chlamydiaepneumoniae.de/pneumoniae/therapie>

- ➔ **Pyrazinamid** <http://www.xerlebnishaft.de/pyrazinamid.pdf>

„... **efflux pump** would be slowed down by low bacterial metabolism. ... It describes the evidence from clinical trials that **PYRAZINAMIDE** is an effective sterilising drug that acts synergistically with rifampicin“

[Bernt - Dieter Huismans](#), Start 2012. Letzte Revision August 2016 [www.Huismans.click](http://www.Huismans.click)



Back to top: [http://www.kabilahsystems.de/chlamydia\\_pneumoniae.pdf](http://www.kabilahsystems.de/chlamydia_pneumoniae.pdf)